An analysis of current neutropenia therapies, including pegfilgrastim

Clinical Cornerstone

Volumn 8, Issue SUPPL. 5, 2006, Pages

  Gabrilove, Janice L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; NAVELBINE; PACLITAXEL; PLACEBO; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUTROPENIA; OVARY CANCER; PATIENT COMPLIANCE; PERIPHERAL BLOOD STEM CELL; PRACTICE GUIDELINE; QUALITY OF LIFE; SINGLE DRUG DOSE; SOLID TUMOR; STEM CELL MOBILIZATION;

EID: 33947283897     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(06)80012-8     Document Type: Article

References (41)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Myeloid growth factors in cancer treatment. Version 1.2006 (2006)
2. Dolan S., Crombez P., and Munoz M. Neutropenia management with granulocyte colony-stimulating factors: From guidelines to nursing practice protocols. Eur J Oncol Nurs 9 Suppl 1 (2005) S14-S23
3. Smith T.J., Khatcheressian J., Lyman G.H., et al. Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
4. Mughal T.I. Current and future use of hematopoietic growth factors in cancer medicine. Hematol Oncol. 22 (2004) 121-134
5. Neupogen (filgrastim) (2004), Amgen Inc, Thousand Oaks, Calif
6. Neulasta (pegfilgrastim) (2004), Amgen Inc, Thousand Oaks, Calif
7. Leukine (sargramostim) (2004), Berlex Laboratories, Inc, Richmond, Calif
8. Heuser M., and Ganser A. Colony-stimulating factors in the management of neutropenia and its complications. Ann Hematol. 84 (2005) 697-708
9. Siena S., Secondino S., Giannetta L., et al. Optimising management of neutropenia and anaemia in cancer chemotherapy advances in cytokine therapy. Crit Rev Oncol/Hematol 48S (2003) S39-S47
10. Kuderer N.M., Crawford J., Dale D.C., et al. Meta-analysis of prophylactic granulocyte colony-stimulating factor in cancer patients receiving chemotherapy. J Support Oncol. 3 Suppl 2 (2005) 50-51
11. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutopenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 23 (2005) 1178-1184
12. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 20 (2002) 727-731
13. Green M.D., Koelbl H., Baselga J., et al. A randomized, double-blind, multicenter, phase III study of fixed-dose, single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 14 (2003) 29-35
14. Siena S., Piccart M., Holmes F.A., et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 10 (2003) 715-724
15. von Minckwitz G., Blohmer J.U., Lohr A., et al. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide in breast cancer patients. J Support Oncol. 3 Suppl 2 (2005) 21-29
16. Bohlius I.F., Greb A., Schwartzer G., et al. The role of granulopoiesis-stimulating factors in the treatment of malignant lymphoma: Recent update of a comprehensive meta-analysis. J Support Oncol. 2 Suppl 2 (2004) 42-43
17. Lopez A., de Sevilla A.F., Castaigne S., et al. Pegfilgrastm supports delivery of CHOP-R chemotherapy administered every 14 days: A randomized phase II study. J Support Oncol. 3 Suppl 1 (2005) 46-47
18. Pro B., Fayad L., McLaughlin P., et al. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47 (2006) 481-485
19. Brusamolino E., Rusconi C., Montalbetti L., et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma. A phase II study of feasibility and toxicity. Haematologica 91 (2006) 496-502
20. Desch C.E., Case D.C., Kalman L.A., et al. Phase II trial of R-CHOP plus maintenance rituximab for previously untreated intermediate- or high-grade non-Hodgkin's lymphoma with filgrastim support for patients older than 60 years. J Support Oncol 3 Suppl 2 (2005) 40-41
21. Engert A., Doehner H., Ho A.D., et al. Pegfilgrastim supports delivery of BEACOPP chemotherapy administered every 14 days. J Support Oncol 3 Suppl 1 (2005) 48-49
22. Younes A., Fayad L., Romaguera J., et al. Single administration of fixed-dose pegfilgrastim in inducing neutrophil count recovery after 170 consecutive days of ABVD chemotherapy in patients with Hodgkin's lymphoma: Safety of pegfilgrastim with every-14-day chemotherapy regimens. J Support Oncol 2 Suppl 2 (2004) 46-47
23. Vose J.M., Crump M., Lazarus H., et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21 (2003) 514-519
24. Grigg A., Solal-Celigny P., Hoskin P., et al. Open-label, randomized study of pegfilgrastm vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 44 (2003) 1503-1508
25. Pirker R., Ulsperger E., Aigner K., et al. A phase II study of pegfilgrastim to support ACE 14 chemotherapy for the treatment of subjects with small cell lung cancer. J Support Oncol 3 Suppl 1 (2005) 44-45
26. Riedel R., Garst J., Dunphy F., et al. Pegfilgrastim supports dose-dense carboplatin/vinorelbine in the treatment of thoracic malignancies. J Support Oncol 2 Suppl 2 (2004) 58-59
27. Bosi A., Szer J., Kassis, et al. A multicenter, double-blind, randomized, phase II trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukemia. J Support Oncol 3 Suppl 1 (2005) 42-43
28. Gabrilove J.L., Jakubowski A., Fain K., et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82 (1988) 1454-1461
29. Isidori A., Tani M., Bonifazi F., et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 90 (2005) 225-231
30. Bruns I., Steidl U., Kronenwett R., et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46 (2006) 180-185
31. Steidl U., Fenk R., Bruns I., et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35 (2005) 33-36
32. Willis F., Pettengell R., Woll P.L., et al. Pegfilgrastim alone successfully mobilized peripheral CD34+ cells in chemotherapy-naive subjects with solid tumors. J Support Oncol 3 Suppl 1 (2005) 66-67
33. Kroschinsky F., Holig K., Poppe-Thiede K., et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 90 (2005) 1665-1671
34. Vansnaelen G., Frere P., Ngirabacu M.C., et al. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 34 (2006) 382-388
35. Jagasia M.H., Greer J., Morgan D.S., et al. Pegfilgrastim after high-dose chemotherapy and autologous stem cell transplant: Phase II study. Bone Marrow Transplant 35 (2005) 1165-1169
36. Staber P.B., Holub R., Linkesch W., et al. Fixed-dose single administration of pegfilgrastim vs daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35 (2005) 889-993
37. Capo G., and Waltzman R. Managing hematological toxicities. J Support Oncol 2 (2004) 65-79
38. Campos L.T., Folbe M., Charu V., et al. Frequency of neutropenia-related events during chemotherapy and the use of pegfilgrastim and filgrastim in community practice: Results of the ACCEPT study. J Support Oncol 3 Suppl 2 (2005) 44-45
39. Weycker D., Hackett J., Edelsberg JS., et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother 40 (2006) 402-407
40. Haithcox S., Ramnes C., Lee H., et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: An observational study. BMC Nurs 19 (2003) 2
41. Wong S.F., and Chan H.O. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy 25 (2005) 372-378